Novel role of oxidants in the molecular mechanism of action of peroxisome proliferators

Antioxidants and Redox Signaling

Volumn 2, Issue 3, 2000, Pages 607-621

  Rusyn, I ^a   Rose, M L ^a   Bojes, H K ^a   Thurman, R G ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; GLYCINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OXIDIZING AGENT; PALMITIC ACID METHYL ESTER; PEROXISOME PROLIFERATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

CELL PROLIFERATION; CYTOKINE PRODUCTION; DNA DAMAGE; HUMAN; LIVER CANCER; LIVER CARCINOGENESIS; MITOGENESIS; NONHUMAN; OXIDATION; PEROXISOME; PRIORITY JOURNAL; REVIEW;

RODENTIA;

EID: 0033753210     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/15230860050192350     Document Type: Review

References (103)

1. Effects of peroxisome proliferators on rat liver phospholipids: Sphingomyelin degradation may be involved in hepatotoxic mechanism of perfluorodecanoic acid
2. Antibodies to tumor necrosis factor-α inhibit liver regeneration after partial hepatectomy
3. Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis
4. The NF-κB and IκB proteins: New discoveries and insights
5. Suppression of liver cell apoptosis in vitro by the non-genotoxic hepatocarcinogen and peroxisome proliferator nafenopin
6. Hepatic peroxisome proliferation in rodents and its significance for humans
7. Tumor necrosis factor-α is a direct hepatocyte mitogen in the rat
8. Peroxisomal proliferators inhibit acyl CoA synthetase and stimulate protein kinase C in vivo
9. Potent peroxisome proliferators inhibit beta-oxidation in the isolated perfused rat liver
10. Peroxisome proliferators activate Kupffer cells in vivo
11. Peroxisome proliferators (PP) activate the production of mitogens by Kupffer cells in vivo: Studies with antibodies to TNFα
12. Mitogenic actions of peroxisome proliferators: Involvement of protein kinase C and tumor necrosis factor α
13. Acyl-CoA synthetase and the peroxisomal enzymes of β-oxidation in human liver
14. Elevated 8-hydroxydeoxyguanosine in hepatic DNA of rats following exposure to peroxisome proliferators: Relationship to carcinogenesis and nuclear localization
15. Age related susceptibility to the carcinogenic effect of the peroxisome proliferator Wy-14,643 in rat liver
16. 2-generating peroxisomal fatty acyl-CoA oxidase
17. Review of the hepatic response to hypopidaemic drugs in rodents and assessment of its toxicological significance to man
18. Possible mechanisms in hepatocarcinogenesis by the peroxisome proliferator di(2-ethylhexyl)phthalate
19. Relationship of oxidative damage to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and Wy-14,643
20. Alteration of protein kinase C isoform-specific expression during rat hepatocarcinogenesis after exposure to the peroxisome proliferator WY-14,643
21. A new method to monitor Kupffer cell function continuously in the perfused rat liver: Dissociation of glycogenolysis from particle phagocytosis
22. Does lowering cholesterol cause cancer?
23. Biologically active products of stimulated liver macrophages (Kupffer cells)
24. Peroxisomes (microbodies and related particles)
25. 4 pathway to inflammation control
26. A cancer risk assessment of di(2-ethylhexyl)phthalate: Application of the new U.S. EPA Risk Assessment Guidelines
27. DNA damage related to increased hydrogen peroxide generation by hypolipidemic drug-induced liver peroxisomes
28. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor natural ligand metabolism
29. Effects of hypolipidemic drugs nafenopin and clofibrate on phenotypic expression and cell death (apoptosis) in altered foci of rat liver
30. Peroxisome proliferation and lipid peroxidation in rat liver
31. Mechanism of action of the nongenotoxic peroxisome proliferators: Role of the peroxisome proliferator-activated receptor alpha
32. Increased susceptibility of aged rats to hepatocarcinogenesis by the peroxisome proliferator nafenopin and the possible involvement of altered liver foci occurring spontaneously
33. Peroxisomal enzyme induction uncoupled from enhanced DNA synthesis in putative preneoplastic liver foci of rats treated with a single dose of the peroxisome proliferator nafenopin
34. 2 production by peroxisomes
35. 2 production in intact liver
36. Tumor necrosis factor receptor-mediated signaling pathways
37. Hepatocarcinogenic potential of di(2-ethylhexyl)phthalate in rodents and its implications for human risk
38. The Helsinki Heart Study: An 8.5-year safety and mortality follow-up
39. A diet containing glycine improves survival in endotoxin shock in the rat
40. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
41. Report of the Conference on Low Blood Cholesterol: Mortality Associations
42. Formation of 8-hydroxydeoxyguanosine in liver DNA of rats following long-term exposure to a peroxisome proliferator
43. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma
44. Mechanisms of hepatocarcinogenicity of peroxisome-proliferating drugs and chemicals
45. Effect of prolonged administration of clofibric acid and di(2-ethylhexyl)phthalate on hepatic enzyme activities and lipid peroxidation in the rat
46. Comparative studies on nafenopin-induced hepatic peroxisome proliferation in the rat, syrian hamster, guinea pig, and marmoset
47. Comparison of the hepatic effects of nafenopin and WY-14,643 on peroxisome proliferation and cell replication in the rat and Syrian hamster
48. Species differences in sequence and activity of the peroxisome proliferator response element (PPRE) within the acyl CoA oxidase gene promoter
49. Low serum cholesterol and the risk of cancer: An analysis of the published prospective studies
50. Rat liver peroxisomes catalyze the β-oxidation of fatty acids
51. The role of peroxisomes in mammalian cellular metabolism
52. A fatty acyl CoA oxidizing system in rat liver peroxisomes: Enhancement by clofibrate, a hypolipidemic drug
53. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators
54. PPAR tissue distribution and interactions with other hormone-signaling pathways
55. Treatment of rats with the peroxisome proliferator ciprofibrate results in increased liver NF-κB activity
56. Biochemical mechanisms of induction of hepatic peroxisome proliferation
57. Addition of peroxisome proliferator-activated receptor alpha to guinea pig hepatocytes confers increased responsiveness to peroxisome proliferators
58. Protein kinase C isotypes and signal-transduction in human neutrophils: Selective substrate specificity of calcium-dependent beta-PKC and novel calcium-independent nPKC
59. Species differences in ciprofibrate induction of hepatic cytochrome P450 4A1 and peroxisome proliferation
60. Mitochondrial and peroxisomal fatty acid oxidation in liver homogenates and isolated hepatocytes from control ciprofibrate-treated rats
61. Relationship of hepatic peroxisome proliferation and replicatives DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643) in rats
62. Contrasting hepatocytic peroxisome proliferation, lipofuscin accumulation and cell replication for the hepatocarcinogens WY-14,643 and clofibric acid
63. Lack of comitogenicity by the peroxisome proliferator hepatocarcinogens, WY-14,643 and clofibiric acid
64. 1 mice (feed study)
65. Comparison of constitutive and inducible levels of expression of peroxisomal β-oxidation and catalase genes in liver and extrahepatic tissues of rat
66. Carcinogenicity of lipid-lowering drugs
67. Catalases
68. Liver-specific catalase expression in transgenic mice inhibits NF-κB activation and DNA synthesis induced by the peroxisome proliferator ciprofibrate
69. The role of protein kinase C in cell surface signal transduction and tumor promotion
70. The molecular heterogeneity of protein kinase C and its implications for cellular regulation
71. Studies on microperoxisomes. V. Are microperoxisomes ubiquitous in mammalian cells?
72. Peroxisome proliferator activated receptor-α expression in human liver
73. Role of PPARα in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator WY-14,643
74. Role of peroxisome proliferator-activated receptor alpha in altered cell cycle regulation in mouse liver
75. Peroxisome proliferator-activated receptor α is restricted to hepatic parenchymal cells, not Kuppfer cells: Implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis
76. Peroxisome proliferators as initiators and promoters of rodent hepatocarcinogenesis
77. Mitochondrial damage by the 'prooxidant' peroxisomal proliferator clofibrate
78. Induction of peroxisome proliferation and hepatic tumours in C57BL/6N mice by ciprofibrate, a hypolipdaemic compound
79. Evidence that ciprofibrate, a potent peroxisome proliferator, is a complete carcinogen in rat
80. Hepatic peroxisome proliferation: Induction by two novel compounds structurally unrelated to clofibrate
81. Carcinogenesis by hepatic peroxisome proliferators: Evaluation of the risk of hypolipidemic drugs and indusrial plasticizers to humans
82. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens
83. Dietary glycine prevents increases in hepatocyte proliferation caused by the peroxisome proliferator WY-14,643
84. Kupffer cells are causally responsible for the mitogenic effect of peroxisome proliferators
85. Kupffer cell oxidant production is central to the mechanism of peroxisome proliferators
86. Role of Kupffer cells in peroxisome proliferator-induced hepatocyte proliferation
87. NADPH oxidase is the source of oxidants for activation of NF-κB by the peroxisome proliferator WY-14,643 (WY)
88. WY-14,643 rapidly activates nuclear factor κB in Kupffer cells before hepatocytes
89. Phthalates rapidly increase reactive oxygen species in vivo
90. Elevated 8-hydroxydeoxyguanosine in hepatic DNA of rats following exposure to peroxisome proliferators: Relationship to mitochondrial alterations
91. Peroxisome proliferator-activated receptors, orphans with ligands and functions
92. Apoptosis and Hepatocarcinogenesis
93. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor
94. PPARgamma in monocytes: Less pain, any gain?
95. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging
96. Species differences in the effects of bezafibrate, a hypolipidemic agent, on hepatic peroxisome-associated enzymes
97. 2 by rat Kupffer cells
98. Glycine: A new anti-inflammatory immunonutrient
99. The potential health effects of phthalate esters in Children's toys: A review and risk assessment
100. Lack of rapid initiating, promoting or sequential syncarcinogenic effects of di(2-ethylhexyl)phthalate in rat liver carcinogenesis
101. The peroxisome proliferator (PP) response element upstream of the human acyl CoA oxidase gene is inactive among a sample human population: Significance for species differences in response to PPs